Certara (NASDAQ:CERT) Price Target Raised to $13.00

Certara (NASDAQ:CERT) had its price target increased by Barclays from $12.00 to $13.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Barclays‘s price target points to a potential upside of 10.08% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. William Blair restated a “market perform” rating on shares of Certara in a research note on Thursday. TD Cowen assumed coverage on Certara in a report on Thursday. They set a “buy” rating and a $16.00 price target for the company. Robert W. Baird cut their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. Finally, Stephens reaffirmed an “overweight” rating and issued a $17.00 price target on shares of Certara in a report on Thursday. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $15.79.

Certara Trading Down 4.8 %

Shares of Certara stock traded down $0.59 during trading on Friday, reaching $11.81. 388,304 shares of the company were exchanged, compared to its average volume of 1,273,163. The business has a 50-day moving average price of $12.43 and a 200-day moving average price of $11.64. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of -59.08, a P/E/G ratio of 9.29 and a beta of 1.57. Certara has a twelve month low of $9.41 and a twelve month high of $19.87.

Hedge Funds Weigh In On Certara

Several hedge funds and other institutional investors have recently modified their holdings of the stock. ArrowMark Colorado Holdings LLC grew its holdings in Certara by 164.2% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock worth $66,171,000 after purchasing an additional 3,861,674 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Certara by 864.0% in the fourth quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company’s stock worth $40,253,000 after purchasing an additional 3,387,590 shares in the last quarter. Brown Brothers Harriman & Co. bought a new position in Certara during the third quarter valued at $27,292,000. Mackenzie Financial Corp bought a new stake in shares of Certara in the 4th quarter worth about $17,852,000. Finally, Wasatch Advisors LP increased its position in Certara by 22.4% during the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after purchasing an additional 1,651,076 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.